bms-986278 + sildenafil

BMS-986278 + sildenafil is an investigational **combination therapy** comprising BMS-986278, a potent and selective oral antagonist of the lysophosphatidic acid receptor 1 (LPA1), and sildenafil, a well-established phosphodiesterase type 5 (PDE5) inhibitor. BMS-986278 is being developed by Bristol Myers Squibb as a novel antifibrotic agent, primarily for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), by inhibiting LPA1-mediated pathways involved in fibrogenesis and lung injury. Sildenafil, widely known for its use in pulmonary arterial hypertension and erectile dysfunction, acts by increasing cyclic GMP via inhibition of PDE5, leading to vasodilation and reduced pulmonary vascular resistance. Combining an LPA1 antagonist (BMS-986278) with sildenafil may leverage antifibrotic and vasodilatory mechanisms, potentially benefiting patients with interstitial lung diseases that have a vascular component. While BMS-986278 has advanced in clinical trials as monotherapy or with background antifibrotic treatment, direct evidence of the specific combination with sildenafil being studied in clinical trials is limited, suggesting this combination may be under early investigation, in preclinical research, or considered as a rational investigative approach based on established drug actions.

Other names

sildenafil